Fallopian Tube Cancer (DBCOND0028487)

Identifiers

Synonyms
Fallopian-tube Cancer / Fallopian Tubes Cancer / Cancer, Fallopian Tube / Cancer of the Fallopian Tube / Fallopian Cancer / Fallopian tube cancer / Carcinoma of fallopian tube (disorder) / Fallopian tube cancer NOS

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Paclitaxel
A taxoid chemotherapeutic agent used as first-line and subsequent therapy for the treatment of advanced carcinoma of the ovary, and other various cancers including breast and lung cancer.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT06063070
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancertreatment2not_yet_recruiting
NCT01767675
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment2active_not_recruiting
NCT01223235
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With BevacizumabtreatmentNot Availablecompleted
NCT03030287
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancertreatment1completed
NCT00086567
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube CancersNo drug interventionsNot AvailableNot Availablecompleted
NCT05281471
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)treatment3recruiting
NCT05579366
PRO1184 for Advanced Solid TumorsNo drug interventionstreatment1 / 2recruiting
NCT05739981
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancertreatment1 / 2recruiting
NCT06617923
Study of Senaparib in Combination With Temozolomidetreatment2not_yet_recruiting
NCT02480374
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancertreatment1completed
NCT03393884
Study of IMNN-001 (also Known As GEN-1) with NACT for Treatment of Ovarian Cancer (OVATION 2)treatment1 / 2active_not_recruiting
NCT03635489
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment3completed
NCT05483933
Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancerstreatment1active_not_recruiting
NCT06483997
Diet, Hepcidin, and Chemotherapy RDINo drug interventionsNot AvailableNot Availablerecruiting
NCT05041257
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)treatment2active_not_recruiting
NCT05220033
Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological CancerNo drug interventionssupportive_careNot Availablerecruiting
NCT05274451
A Study to Investigate LYL797 in Adults with Solid TumorsNo drug interventionstreatment1recruiting
NCT05377996
A Study of XMT-1660 in Participants With Solid TumorsNo drug interventionstreatment1recruiting
NCT05445778
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)treatment3recruiting
NCT05891197
A Biomarker Screening Protocol for Participants With Solid TumorsNo drug interventionsNot AvailableNot Availablerecruiting
NCT06084416
A Study of Sovilnesib in Subjects with Ovarian CancerNo drug interventionstreatment1recruiting
NCT06602063
Surgery for Ovarian Cancer After PARPi Therapy in Precisiontreatment1 / 2not_yet_recruiting
NCT00028743
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancertreatment3completed
NCT03283943
PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.treatment1unknown_status
NCT03029403
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancertreatment2active_not_recruiting
NCT00637390
A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.treatment1terminated
NCT00014690
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment2completed
NCT00262990
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancertreatment3completed
NCT05261490
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancertreatment1 / 2terminated
NCT05622890
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancertreatment3recruiting
NCT00012090
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneumtreatment2completed
NCT00004064
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancertreatment2unknown_status
NCT03213964
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Inttreatment1completed
NCT03585764
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerNo drug interventionstreatment1terminated
NCT00003064
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancertreatment1 / 2unknown_status
NCT02595021
Total/Subtotal Colectomy in Ovarian CancerNo drug interventionstreatment2unknown_status
NCT04598321
BrUOG 390: Neoadjuvant Treatment With Talazoparibtreatment1terminated
NCT03150121
Biomarkers for Early Detection of Ovarian Cancer Using Uterine LavageNo drug interventionsdiagnosticNot Availablerecruiting
NCT00517621
Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnairetreatment2completed
NCT01744821
Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal CancerNo drug interventionspreventionNot Availableterminated
NCT05043402
A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancertreatment3unknown_status
NCT04537702
Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer PatientsNo drug interventionssupportive_careNot Availablecompleted
NCT03905902
DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal CarcinomaNo drug interventionstreatment3withdrawn
NCT04515602
Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS)No drug interventionstreatment3not_yet_recruiting
NCT00085384
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancertreatment1 / 2terminated
NCT05788484
A Study of CDX-585 in Patients With Advanced MalignanciesNo drug interventionstreatment1recruiting
NCT00550784
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancertreatment1completed
NCT04510584
Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancertreatment2withdrawn
NCT01652079
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancertreatment2completed
NCT03759587
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancertreatment2completed
NCT00870233
Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of LifeNo drug interventionsNot AvailableNot Availablecompleted
NCT03056833
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancertreatment1completed
NCT04402333
Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & SurvivalNo drug interventionsNot AvailableNot Availableunknown_status
NCT01281254
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)treatment3terminated
NCT05792254
Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal CancerNo drug interventionstreatmentNot Availablenot_yet_recruiting
NCT00369954
Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatintreatment2withdrawn
NCT01220154
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancertreatment1unknown_status
NCT05287451
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort StudyNo drug interventionspreventionNot Availablerecruiting
NCT03771651
Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tubetreatment0active_not_recruiting
NCT00066651
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumorstreatment1completed
NCT01442051
Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian CancerNo drug interventionstreatmentNot Availablecompleted
NCT04991051
Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT03604653
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal CancersNot AvailableNot Availablecompleted
NCT04295577
Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceRNo drug interventionsNot AvailableNot Availableunknown_status
NCT03872947
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumorstreatment1recruiting
NCT00022347
TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment2completed
NCT04516447
A Study of ZN-c3 in Patients With Ovarian Cancertreatment1recruiting
NCT00003345
Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancertreatment2completed
NCT04701645
Microdevice In Ovarian, Fallopian Tube, And Peritoneal CancerNo drug interventionsdiagnostic1recruiting
NCT00295945
Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic CancerNot AvailableNot Availablecompleted
NCT05446298
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancertreatment2recruiting
NCT02606305
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancertreatment1 / 2completed
NCT00582205
Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinomatreatment2terminated
NCT00045461
Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancertreatment2 / 3unknown_status
NCT00019461
Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT02824328
A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic CancersNo drug interventionsNot AvailableNot Availablecompleted
NCT00653328
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinomatreatment2terminated
NCT00382811
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancertreatment3completed
NCT06290193
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive SurgeryNo drug interventionstreatment2recruiting
NCT00096993
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancertreatment2completed
NCT00334893
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancertreatment2completed
NCT00098878
Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment3completed
NCT02759588
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancertreatment1 / 2completed
NCT06024109
Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total HysterectomyNo drug interventionsNot AvailableNot Availablerecruiting
NCT04029909
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancertreatment1unknown_status
NCT01506856
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trialtreatment2 / 3completed
NCT05080556
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancertreatment2recruiting
NCT00039585
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumortreatment2completed
NCT00003385
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancertreatment1completed
NCT04229615
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapytreatment3unknown_status
NCT01083537
Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstructiontreatment1 / 2terminated
NCT06173037
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerNo drug interventionstreatment2recruiting
NCT00588237
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancertreatment2completed
NCT00281632
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancertreatment2completed
NCT03759600
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancertreatment2completed
NCT00288275
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube CancerNo drug interventionsNot AvailableNot Availableterminated
NCT02834975
Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).treatment2terminated
NCT00318370
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapytreatment2completed
NCT00006942
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT04846842
A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancertreatment2unknown_status
NCT01144442
WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian CancertreatmentNot Availableterminated
NCT02470299
Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patientsbasic_scienceNot Availableactive_not_recruiting
NCT01899599
PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancertreatment2completed
NCT01610206
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancertreatment2completed
NCT00601406
Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological CancerNo drug interventionstreatmentNot Availableunknown_status
NCT03783949
European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancertreatment2completed
NCT02487849
HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinomatreatment2withdrawn
NCT02928549
Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative StudyNo drug interventionsNot AvailableNot Availablecompleted
NCT01204749
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancertreatment3completed
NCT05858736
Safety, PK and Efficacy of AI-061 in Advanced Solid TumorsNo drug interventionstreatment1recruiting
NCT00770536
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CRtreatment1completed
NCT00520013
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumorstreatment2completed
NCT01216813
Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT00059618
PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancertreatment1completed
NCT01556841
The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancertreatment2completed
NCT06274541
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA StudyNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT00006041
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal CancerNo drug interventionstreatment1completed
NCT00616941
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment1completed
NCT01196741
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancertreatment2 / 3completed
NCT00479817
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancertreatment2completed
NCT00017017
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancertreatment1 / 2completed
NCT00373217
Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancertreatment2terminated
NCT03540017
HIPEC After Initial CRS in Patients Who Have Received NACTtreatment1recruiting
NCT00003634
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapytreatment2unknown_status
NCT00004934
Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancertreatment3completed
NCT00390234
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcomatreatment2completed
NCT00003624
Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancersupportive_care2terminated
NCT05538624
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovarytreatment1 / 2terminated
NCT01972516
Tivozanib As Maintenance Therapy In GYNtreatment2terminated
NCT00993616
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatintreatment2completed
NCT04025216
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancerstreatment1terminated
NCT00003358
Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment1completed
NCT00905658
Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological CancerNo drug interventionssupportive_care2unknown_status
NCT03373058
Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive SurgeryNo drug interventionstreatment3unknown_status
NCT02349958
Clinical Trial of Intraperitoneal Hyperthermic ChemotherapyNo drug interventionstreatment2unknown_status
NCT03921658
The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT01905163
Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive PatientsNo drug interventionstreatment2completed
NCT05236686
Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian CancerNo drug interventionstreatmentNot Availablenot_yet_recruiting
NCT00466986
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancertreatment2completed
NCT06342986
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancertreatment1recruiting
NCT02324439
Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in RemissionNo drug interventionsprevention1completed
NCT00096239
CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancertreatment2completed
NCT00897039
Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerNo drug interventionsNot AvailableNot Availableunknown_status
NCT01766622
18F-CP18 Imaging Studies for Cancer Treatment With BirinapantNo drug interventionsdiagnostic2withdrawn
NCT04227522
Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patientstreatment3active_not_recruiting
NCT00669422
ChemoFx® PRO - A Post-Market Data Collection StudyNo drug interventionsNot AvailableNot Availableterminated
NCT02534922
Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancertreatment1unknown_status
NCT00263822
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancertreatment3completed
NCT02728830
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancerstreatment0completed
NCT05960630
MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian CancerNo drug interventionstreatmentNot Availablerecruiting
NCT00903630
Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment1 / 2terminated
NCT00079430
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment1completed
NCT02884648
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgerytreatment2recruiting
NCT00357448
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancertreatment1completed
NCT03693248
Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancertreatment3unknown_status
NCT03983226
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)treatment2recruiting
NCT01669226
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancertreatment2completed
NCT02433626
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignanciestreatment1unknown_status
NCT04590326
A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018treatment1 / 2recruiting
NCT00114166
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT05009082
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancertreatment3recruiting
NCT03621982
Study of ADCT-301 in Patients With Selected Advanced Solid Tumorstreatment1terminated
NCT00004082
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumorstreatment1completed
NCT05001282
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)No drug interventionstreatment1 / 2terminated
NCT00483782
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancertreatment3completed
NCT00538031
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT00989131
Study of Paclitaxel in Patients With Ovarian Cancertreatment3completed
NCT00569673
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancertreatment2completed
NCT05574673
Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination PhenotypeNo drug interventionsNot AvailableNot Availablerecruiting
NCT00157573
GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancertreatment2completed
NCT00748527
Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment2terminated
NCT01188876
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancertreatment1 / 2completed
NCT01312376
Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancertreatment1terminated
NCT03355976
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomastreatment2active_not_recruiting
NCT03891576
Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer)treatment2active_not_recruiting
NCT03332576
Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancertreatment1completed
NCT05092360
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)treatment3active_not_recruiting
NCT00157560
Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian CarcinomaNo drug interventionstreatment2completed
NCT00003160
Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinumtreatment2unknown_status
NCT00002960
SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)treatment1completed
NCT00634894
Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment2withdrawn
NCT00006391
Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment1completed
NCT00032162
Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancertreatment1 / 2completed
NCT01248962
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancertreatment2completed
NCT00003380
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancertreatment1terminated
NCT00856180
Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignanciestreatment2completed
NCT00753480
A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerNo drug interventionstreatment1suspended
NCT03648489
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)treatment2unknown_status
NCT02725489
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancerstreatment2completed
NCT02657889
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancertreatment1 / 2completed
NCT06087289
A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment1 / 2recruiting
NCT00421889
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatmenttreatment1 / 2completed
NCT05086692
A Beta-only IL-2 ImmunoTherapY Studytreatment1 / 2recruiting
NCT02012192
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancertreatment1 / 2terminated
NCT00501644
Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancertreatment2completed
NCT01308944
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patientstreatment1completed
NCT02855944
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patientstreatment3completed
NCT01666444
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancertreatment2completed
NCT03363867
BEACON - ABC in Recurrent Platinum Resistant HGSOCtreatment2active_not_recruiting
NCT01100372
Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancertreatment2unknown_status
NCT03159572
Homologous Recombination Inquiry Through Ovarian Malignancy InvestigationsNo drug interventionsNot AvailableNot Availablecompleted
NCT00850772
Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian CancerNo drug interventionssupportive_care3completed
NCT00317772
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancertreatment1 / 2completed
NCT05199272
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid MalignanciesNo drug interventionstreatment1 / 2active_not_recruiting
NCT06161272
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPitreatment2not_yet_recruiting
NCT05912972
Development and Management of Registry in Patients With Gynecologic Cancer in KoreaNo drug interventionsNot AvailableNot Availablerecruiting
NCT04657068
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumorstreatment1 / 2recruiting
NCT00052468
Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancertreatment3completed
NCT04027868
Genomic BRCA and Extensive ovArian Cancer TestingNo drug interventionsNot AvailableNot Availablecompleted
NCT01610869
Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancertreatment2completed
NCT00030446
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT05080946
Using Aspirin to Improve Immunological Features of Ovarian Tumorstreatment0recruiting
NCT03522246
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapytreatment3active_not_recruiting
NCT00075712
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancertreatment2 / 3completed
NCT00428610
A Study of Chemotherapy Treatment for Patients With Ovarian Cancertreatment2completed
NCT01253681
Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancertreatment1completed
NCT00006981
Immunotoxin Therapy in Treating Patients With Advanced Cancertreatment1completed
NCT04889495
A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerNot AvailableNot Availablenot_yet_recruiting
NCT00005095
Specimen and Data Study for Ovarian Cancer Early Detection and PreventionNo drug interventionsNot AvailableNot Availablerecruiting
NCT00672295
PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancertreatment1completed
NCT00055614
Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment1completed
NCT04209855
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expressiontreatment3active_not_recruiting
NCT03607955
Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapytreatment1withdrawn
NCT03093155
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumabtreatment2completed
NCT00217555
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancertreatment2completed
NCT03480750
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancertreatment1 / 2completed
NCT00866723
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancertreatment2terminated
NCT02915523
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancertreatment1 / 2completed
NCT05665023
Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinomatreatment2recruiting
NCT03189108
Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid TumorsNo drug interventionsNot AvailableNot Availablecompleted
NCT00008138
S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancertreatment2completed
NCT02859038
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)No drug interventionstreatment3unknown_status
NCT03657043
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)treatment2completed
NCT04440943
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced MalignanciesNo drug interventionstreatment1completed
NCT04296890
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expressiontreatment3completed
NCT02121990
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancertreatment1completed
NCT06014190
HS-20089 in Patients With Ovarian Cancer and Endometrial CancerNo drug interventionstreatment2recruiting
NCT00459290
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment2completed
NCT05200364
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancertreatment1active_not_recruiting
NCT05065021
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitortreatment2recruiting
NCT02124421
HOT: HIPEC in Ovarian Cancer as Initial Treatmenttreatment2active_not_recruiting
NCT06445621
Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker TestNo drug interventionsNot AvailableNot Availablerecruiting
NCT05527184
First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancersNo drug interventionstreatment1recruiting
NCT04028479
The Registry of Oncology Outcomes Associated With Testing and TreatmentNo drug interventionsNot AvailableNot Availablerecruiting
NCT00010179
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancertreatment2completed
NCT00059787
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinomatreatment2completed
NCT00053833
S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment2terminated
NCT00006454
Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancertreatment3completed
NCT01659554
A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancerstreatment2terminated
NCT00031954
Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancertreatment2completed
NCT01391351
Search for Predictors of Therapeutic Response in Ovarian CarcinomaNo drug interventionsNot AvailableNot Availablecompleted
NCT01704651
Accelerating Gastrointestinal Recoveryprevention3completed
NCT00574951
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment2terminated
NCT00189553
Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapsetreatment3completed
NCT01219777
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovariantreatment1completed
NCT00091377
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment1 / 2completed
NCT03180177
Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian CancerNo drug interventionstreatment3unknown_status
NCT03924245
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancerstreatment1terminated
NCT00005645
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatmenttreatment2withdrawn
NCT05329545
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)treatment3terminated
NCT03054298
CAR T Cells in Mesothelin Expressing CancersNo drug interventionstreatment1completed
NCT01669798
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancertreatment2completed
NCT01074398
Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182No drug interventionsNot AvailableNot Availableunknown_status
NCT01493505
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancertreatment3terminated
NCT00033605
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvissupportive_care3completed
NCT01883297
"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment1active_not_recruiting
NCT05801783
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian CancerNo drug interventionstreatment0recruiting
NCT01471483
Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian CancerNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT02278783
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancertreatment2terminated
NCT04575961
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancertreatment2recruiting
NCT00505661
Letrozole in Patients With Ovarian Tumorstreatment2terminated
NCT04201561
High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathyprevention3active_not_recruiting
NCT01091428
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancertreatment2completed
NCT01851928
Validation of a Nutrition Screening ToolNo drug interventionsNot AvailableNot Availablecompleted
NCT00275028
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancertreatment2completed
NCT02865811
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancertreatment2completed
NCT04204811
Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant ChemotherapyNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT00429793
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT00418093
Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinomatreatment2terminated
NCT00293293
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicinesupportive_careNot Availablecompleted
NCT01402271
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancertreatment1 / 2completed
NCT01137071
Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancertreatment2terminated
NCT00381888
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancertreatment2completed
NCT03321188
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patientstreatment2recruiting
NCT00303888
Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancertreatment1terminated
NCT05887609
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparibtreatment2recruiting
NCT00838656
Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment2unknown_status
NCT00049556
Gefitinib in Treating Patients With Cervical Cancertreatment2completed
NCT04375956
Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patientstreatment2recruiting
NCT00287885
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancertreatment1completed
NCT05456685
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancertreatment2active_not_recruiting
NCT02661815
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancertreatment1terminated
NCT01482715
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)treatment1 / 2completed
NCT00436215
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancertreatment2completed
NCT00226915
Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinomatreatment3completed
NCT05071937
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancertreatment2recruiting
NCT01166737
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian CancerNo drug interventionsotherNot Availablecompleted
NCT01079832
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological MalignanciesNo drug interventionstreatment2completed
NCT01306032
Phase II ABT-888 With Cyclophosphamidetreatment2completed
NCT00019552
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancertreatment2completed
NCT00842452
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgerytreatment1completed
NCT00478452
Dendritic Cell Vaccine for High Risk Ovarian Cancer Patientstreatment1completed
NCT03430700
Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancertreatment2active_not_recruiting
NCT00002600
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancertreatment1completed
NCT00910000
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancertreatment1 / 2terminated
NCT00692900
Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancertreatment1completed
NCT03038100
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment3completed
NCT05460000
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapytreatment2not_yet_recruiting
NCT01091259
Irinotecan and Bevacizumab for Recurrent Ovarian Cancertreatment2completed
NCT03188159
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancertreatment2unknown_status
NCT01196559
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancertreatment2completed
NCT00287859
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancertreatment1terminated
NCT00045175
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancertreatment1completed
NCT04814875
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapytreatment1 / 2terminated
NCT02452775
Autologous OC-L Vaccine and Ovarian CancerNo drug interventionstreatment1terminated
NCT05429970
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)preventionNot Availablerecruiting
NCT00408070
Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancertreatment2terminated
NCT00238342
Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic MassNo drug interventionsdiagnosticNot Availableunknown_status
NCT00138242
Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancertreatment2completed
NCT00693342
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remissiontreatment3withdrawn
NCT00230542
Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancertreatment2completed
NCT00126542
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancertreatment2completed
NCT00702299
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancertreatment1completed
NCT01670799
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancerother0completed
NCT01170299
Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal CancerNo drug interventionssupportive_careNot Availablecompleted
NCT00652899
Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancertreatment2terminated
NCT01447706
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancerstreatment2completed
NCT02489006
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancertreatment2active_not_recruiting
NCT01582906
A Survivorship Care Plan for Gynaecological Cancer PatientsNo drug interventionsNot AvailableNot Availablecompleted
NCT01649336
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancertreatment1completed
NCT00003636
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancertreatment3completed
NCT01968213
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)treatment3completed
NCT02668913
LCC-CARIS-01: Molecular Profiling in Gynaecological CancerNo drug interventionsdiagnosticNot Availablecompleted
NCT00268918
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patientstreatment1completed
NCT00652119
Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origintreatment1unknown_status
NCT06545617
A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancertreatment1 / 2not_yet_recruiting
NCT00526617
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patientstreatment1completed
NCT04676334
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparibtreatment3completed
NCT00021034
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment1completed
NCT03311334
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumorstreatment1 / 2terminated
NCT00003334
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tracttreatment2completed
NCT05179824
Tempus Priority Study: A Pan-tumor Observational StudyNo drug interventionsNot AvailableNot Availablerecruiting
NCT05708924
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancertreatment1suspended
NCT03839524
A Trial Evaluating TG4050 in Ovarian Carcinoma.No drug interventionstreatment1active_not_recruiting
NCT00003896
S9912 Combination Chemo in Stage III Ovarian Cancer,treatment2completed
NCT00267696
Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancertreatment2completed
NCT00085358
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)treatment1completed
NCT01035658
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinomatreatment1 / 2terminated
NCT02489058
A Study of Long-Term Responders on OlaparibNo drug interventionsNot AvailableNot Availablecompleted
NCT01296035
Panitumumab and Gemcitabine in Relapsed Ovarian Cancertreatment2terminated
NCT00058435
Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancertreatment1completed
NCT00006235
Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment1completed
NCT06451263
Nudge to Gynecologic OncologyNo drug interventionssupportive_careNot Availableactive_not_recruiting
NCT03748186
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancerstreatment1completed
NCT02435186
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancertreatment2unknown_status
NCT01370122
Pelvic Floor Disorders in Survivors of Gynecologic MalignanciesNo drug interventionsNot AvailableNot Availablecompleted
NCT00331422
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancertreatment2terminated
NCT00005025
Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancertreatment2unknown_status
NCT02571725
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancertreatment1 / 2active_not_recruiting
NCT04368130
SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer CareNo drug interventionssupportive_careNot Availablewithdrawn
NCT05870748
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1treatment2 / 3recruiting
NCT00504257
Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinomatreatment2completed
NCT00112957
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancertreatment2completed
NCT01663857
A Study LY2228820 for Recurrent Ovarian Cancertreatment1 / 2completed
NCT02948426
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancertreatment1terminated
NCT04442126
A Study of NM21-1480 in Adult Patients With Advanced Solid TumorsNo drug interventionstreatment1 / 2terminated
NCT00189566
Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapsetreatment2completed
NCT03740165
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)treatment3active_not_recruiting
NCT00004074
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neutreatment1completed
NCT01276574
Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CTNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT00003120
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remissiontreatment3completed
NCT00801320
Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal CancerNo drug interventionsotherNot Availablecompleted
NCT01570582
A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancertreatment2unknown_status
NCT00003382
Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancertreatment1terminated
NCT00959582
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)No drug interventionsdiagnostic1completed
NCT04546373
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian CancerNot AvailableNot Availablecompleted
NCT00617773
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment2completed
NCT04539327
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO StudyNot AvailableNot Availablecompleted
NCT05256576
KORE-Innovation: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients With Ovarian CancerNo drug interventionshealth_services_researchNot Availablerecruiting
NCT02631876
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancertreatment3completed
NCT03367260
The Treatment Preferences of Women Diagnosed With Ovarian CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT00003560
Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment2unknown_status
NCT05200260
Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancertreatment2not_yet_recruiting
NCT00004060
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancertreatment2completed
NCT00466960
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapytreatment2completed
NCT00087191
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerdiagnosticNot Availableterminated
NCT00721162
Study of Ramucirumab in Ovarian Cancertreatment2completed
NCT01065662
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignanciestreatment1completed
NCT02873962
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparibtreatment2active_not_recruiting
NCT00041080
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment3completed
NCT00066729
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment1completed
NCT00217529
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancertreatment1 / 2completed
NCT00872989
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancertreatment2completed
NCT01312389
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancertreatment1 / 2terminated
NCT03000192
HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday LifeNo drug interventionsNot AvailableNot Availableunknown_status
NCT00343044
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancerstreatment2completed
NCT05537844
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous CarcinomaNo drug interventionsNot AvailableNot Availablerecruiting
NCT00768144
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinomatreatment2completed
NCT00003944
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT01891344
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)treatment2completed
NCT01262040
Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally InvasiveNo drug interventionsdiagnosticNot Availablecompleted
NCT00562640
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)treatment1completed
NCT00072267
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment2completed
NCT01237067
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancerstreatment1completed
NCT06184867
Choices About Genetic Testing And Learning Your Risk With Smart TechnologyNo drug interventionshealth_services_research0recruiting
NCT00003967
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancertreatment1completed
NCT00182767
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancertreatment1 / 2completed
NCT00522301
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remissiontreatment2terminated
NCT00354601
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancertreatment2terminated
NCT00436501
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancertreatment1 / 2completed
NCT03824704
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)treatment2terminated
NCT05198804
A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancertreatment1 / 2active_not_recruiting
NCT00515372
Depression Treatment and Screening in Ovarian Cancer PatientsNo drug interventionstreatment1active_not_recruiting
NCT01591772
Structural and Functional Imaging and Cognitive Functions in Ovarian CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT01661868
Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancertreatment2withdrawn
NCT00803569
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancerstreatment1completed
NCT03849469
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumorstreatment1completed
NCT03126812
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancertreatment1 / 2completed
NCT00028912
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancertreatment1completed
NCT00499512
Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube CancerNo drug interventionsNot AvailableNot Availableunknown_status
NCT00004012
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancertreatment2completed
NCT00799110
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimodtreatment2active_not_recruiting
NCT00322881
Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancertreatment2terminated
NCT03593681
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of MalignancyNo drug interventionsNot AvailableNot Availablecompleted
NCT01031381
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancertreatment2completed
NCT01096381
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid TumorNo drug interventionsNot AvailableNot Availableterminated
NCT06469281
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancerstreatment1recruiting
NCT00002895
Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal CancerNo drug interventionstreatment3completed
NCT01146795
Neoadjuvant Therapy for Ovarian Cancertreatment2completed
NCT03312114
Anti-PD-L1 and SAbR for Ovarian Cancertreatment2terminated
NCT01048814
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer CasesNo drug interventionsNot AvailableNot Availablecompleted
NCT01626014
Interactive Educational Website for Women With Ovarian Cancer & CaregiversNo drug interventionssupportive_care0completed
NCT01281514
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancertreatment1completed
NCT00993655
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancertreatment2completed
NCT02262455
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumorstreatment1completed
NCT03329950
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignanciestreatment1completed
NCT00245050
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancersupportive_care3completed
NCT04983550
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOCtreatment2unknown_status
NCT01105650
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancertreatment2completed
NCT02973750
Determinants of Age-Related Treatment Effectiveness in Ovarian CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT04406623
Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian CancerNo drug interventionstreatment1completed
NCT04001023
Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting HypoxiaNo drug interventionstreatmentNot Availablerecruiting
NCT00536523
Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal CancerNo drug interventionsNot AvailableNot Availableterminated
NCT00061308
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancertreatment2completed
NCT00305838
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifendiagnostic2unknown_status
NCT00002538
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal CancersNo drug interventionstreatment2completed
NCT01416038
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancertreatment1completed
NCT00543049
Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitortreatment2completed
NCT02728622
Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxanetreatment3completed
NCT00189358
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapytreatment2completed
NCT01104675
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancertreatment2completed
NCT01580696
Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancertreatment1 / 2completed